Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$13.81
-6.0%
$14.27
$8.50
$20.76
$2.35B2.161.78 million shs1.52 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$40.00
-7.3%
$53.90
$22.16
$60.08
$1.75B0.61323,920 shs976,061 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.86
-1.1%
$2.02
$0.54
$7.13
$567.60M1.7959,263 shs719,050 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$19.95
-4.1%
$19.77
$10.41
$44.14
$2.20B0.262.73 million shs4.07 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
0.00%+4.18%-1.01%-6.85%+66.84%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-18.84%-26.42%-18.67%+122.59%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%-1.05%+1.62%+0.53%+193.61%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%-0.38%-5.02%+12.43%-43.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$13.81
-6.0%
$14.27
$8.50
$20.76
$2.35B2.161.78 million shs1.52 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$40.00
-7.3%
$53.90
$22.16
$60.08
$1.75B0.61323,920 shs976,061 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.86
-1.1%
$2.02
$0.54
$7.13
$567.60M1.7959,263 shs719,050 shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$19.95
-4.1%
$19.77
$10.41
$44.14
$2.20B0.262.73 million shs4.07 million shs
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
0.00%+4.18%-1.01%-6.85%+66.84%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-18.84%-26.42%-18.67%+122.59%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%-1.05%+1.62%+0.53%+193.61%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%-0.38%-5.02%+12.43%-43.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.63
Moderate Buy$20.0044.82% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.43
Hold$42.406.00% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.50
Moderate Buy$7.40297.85% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.11
Hold$27.7138.89% Upside

Current Analyst Ratings Breakdown

Latest PROK, SRPT, PAHC, and ADPT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Boost Price TargetBuy$19.00 ➝ $21.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Lower Price TargetOverweight$21.00 ➝ $19.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy$21.00
5/6/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingBuy$22.00
4/22/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
UpgradeSell (D-)Sell (D)
4/21/2026
ProKidney Corp. stock logo
PROK
ProKidney
Reiterated RatingSell (D-)
4/20/2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Reiterated RatingSell (D-)
4/16/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Reiterated RatingSell
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageNeutral$62.00
4/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Initiated CoverageHold$62.00
4/7/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Boost Price TargetSector Perform$18.00 ➝ $19.00
(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$276.98M7.98N/AN/A$1.40 per share9.86
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.30B1.25$3.03 per share13.20$8.93 per share4.48
ProKidney Corp. stock logo
PROK
ProKidney
$890K630.98N/AN/A($3.36) per share-0.55
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$2.20B0.96N/AN/A$14.26 per share1.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$59.50M-$0.33N/AN/AN/A-16.82%-40.06%-16.64%N/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3317.1712.200.666.35%37.14%8.57%6/30/2026 (Confirmed)
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.52N/AN/AN/A-7,725.20%N/A-18.83%5/11/2026 (Estimated)
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$8.44N/A9.880.32-2.94%7.56%2.94%N/A

Latest PROK, SRPT, PAHC, and ADPT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.13N/AN/AN/A$0.10 millionN/A
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
5/6/2026Q1 2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$0.9760$3.16+$2.1840$2.88$474.16 million$730.80 million
5/5/2026Q1 2026
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.16-$0.13+$0.03-$0.13$61.03 million$70.87 million
3/18/2026Q4 2025
ProKidney Corp. stock logo
PROK
ProKidney
-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 million
2/25/2026Q4 2025
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$0.87-$3.58-$2.71-$3.93$390.95 million$442.93 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.20%N/A20.60%N/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A

Latest PROK, SRPT, PAHC, and ADPT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.120.85%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
3.35
3.23
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.22
ProKidney Corp. stock logo
PROK
ProKidney
N/A
9.13
9.13
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.56
4.63
1.48

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
5.70%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.13%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790160.04 million150.92 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.53 million20.22 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
3301.92 million181.66 millionOptionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,372105.58 million98.29 millionOptionable

Recent News About These Companies

Sarepta (SRPT) Q1 2026 Earnings Transcript
Sarepta Therapeutics Q1 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$13.81 -0.88 (-5.99%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$13.88 +0.06 (+0.47%)
As of 05/8/2026 07:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$40.00 -3.16 (-7.32%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$41.08 +1.08 (+2.70%)
As of 05/8/2026 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

ProKidney stock logo

ProKidney NASDAQ:PROK

$1.86 -0.02 (-1.06%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$1.90 +0.03 (+1.88%)
As of 05/8/2026 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$19.95 -0.85 (-4.09%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$20.00 +0.05 (+0.25%)
As of 05/8/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.